News
A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...
July is Chronic Disease Awareness Month and serves as an important reminder to take charge of your health and get informed about potential health risks. Dr. Samantha Picking, ...
Child mortality has been halved in the last 25 years. Building on this progress, new innovations in immunization are working ...
A new CHOP study found only one in three eligible patients took Beyfortus when the medication that protects against severe ...
WHO includes ArkBio' paediatric RSV drug, ziresovir in PADO-RSV priority list: Shanghai, China Thursday, July 17, 2025, 14:00 Hrs [IST] Shanghai Ark Biopharmaceutical Co., Ltd. (A ...
The Australian Medical Association fears WA is in the midst of one of the state's worst flu seasons as cases soar and ...
Explore more
Frailty was a significant predictor of severe outcomes and hospitalization characteristics in older adults hospitalized with RSV infection.
1d
Vietnam Investment Review on MSNArkBio s RSV Drug Added to WHO Pediatric Priority ListIn the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by Global Accelerator for Paediatric formulations (GAP-f), the World Health Organization ...
“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...
Arexvy is currently approved to prevent lower respiratory tract disease (LRTD) caused by RSV in individuals aged 60 years and older, and those 50 to 59 years of age who are at increased risk for LRTD ...
FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results